200 related articles for article (PubMed ID: 16365423)
1. Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects.
Buhtoiarov IN; Lum HD; Berke G; Sondel PM; Rakhmilevich AL
J Immunol; 2006 Jan; 176(1):309-18. PubMed ID: 16365423
[TBL] [Abstract][Full Text] [Related]
2. CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro.
Buhtoiarov IN; Lum H; Berke G; Paulnock DM; Sondel PM; Rakhmilevich AL
J Immunol; 2005 May; 174(10):6013-22. PubMed ID: 15879094
[TBL] [Abstract][Full Text] [Related]
3. In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages.
Lum HD; Buhtoiarov IN; Schmidt BE; Berke G; Paulnock DM; Sondel PM; Rakhmilevich AL
J Leukoc Biol; 2006 Jun; 79(6):1181-92. PubMed ID: 16565324
[TBL] [Abstract][Full Text] [Related]
4. Naive mouse macrophages become activated following recognition of L5178Y lymphoma cells via concurrent ligation of CD40, NKG2D, and CD18 molecules.
Buhtoiarov IN; Rakhmilevich AL; Lanier LL; Ranheim EA; Sondel PM
J Immunol; 2009 Feb; 182(4):1940-53. PubMed ID: 19201847
[TBL] [Abstract][Full Text] [Related]
5. Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides.
Buhtoiarov IN; Sondel PM; Eickhoff JC; Rakhmilevich AL
Immunology; 2007 Mar; 120(3):412-23. PubMed ID: 17163960
[TBL] [Abstract][Full Text] [Related]
6. Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.
Rakhmilevich AL; Felder M; Lever L; Slowinski J; Rasmussen K; Hoefges A; Van De Voort TJ; Loibner H; Korman AJ; Gillies SD; Sondel PM
J Immunol; 2017 Feb; 198(4):1575-1584. PubMed ID: 28062694
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages.
Buhtoiarov IN; Sondel PM; Wigginton JM; Buhtoiarova TN; Yanke EM; Mahvi DA; Rakhmilevich AL
Immunology; 2011 Feb; 132(2):226-39. PubMed ID: 21039467
[TBL] [Abstract][Full Text] [Related]
8. Low expression of CD40 and B7 on macrophages infiltrating UV-exposed human skin; role in IL-2Ralpha-T cell activation.
Kremer IB; Cooper KD; Teunissen MB; Stevens SR
Eur J Immunol; 1998 Sep; 28(9):2936-46. PubMed ID: 9754581
[TBL] [Abstract][Full Text] [Related]
9. Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice.
Johnson EE; Buhtoiarov IN; Baldeshwiler MJ; Felder MA; Van Rooijen N; Sondel PM; Rakhmilevich AL
J Immunother; 2011 Jan; 34(1):76-84. PubMed ID: 21150715
[TBL] [Abstract][Full Text] [Related]
10. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.
Carpenter EL; Mick R; Rüter J; Vonderheide RH
J Transl Med; 2009 Nov; 7():93. PubMed ID: 19906293
[TBL] [Abstract][Full Text] [Related]
11. CD40 ligation in vivo induces bystander proliferation of memory phenotype CD8 T cells.
Koschella M; Voehringer D; Pircher H
J Immunol; 2004 Apr; 172(8):4804-11. PubMed ID: 15067057
[TBL] [Abstract][Full Text] [Related]
12. Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia.
Wu QL; Buhtoiarov IN; Sondel PM; Rakhmilevich AL; Ranheim EA
J Immunol; 2009 Jun; 182(11):6771-8. PubMed ID: 19454672
[TBL] [Abstract][Full Text] [Related]
13. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells.
Roda JM; Parihar R; Carson WE
J Immunol; 2005 Aug; 175(3):1619-27. PubMed ID: 16034101
[TBL] [Abstract][Full Text] [Related]
14. CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody.
Hiramatsu K; Serada S; Kobiyama K; Nakagawa S; Morimoto A; Matsuzaki S; Ueda Y; Fujimoto M; Yoshino K; Ishii KJ; Enomoto T; Kimura T; Naka T
Cancer Sci; 2015 Oct; 106(10):1474-8. PubMed ID: 26498112
[TBL] [Abstract][Full Text] [Related]
15. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2.
Alleva DG; Burger CJ; Elgert KD
J Immunol; 1994 Aug; 153(4):1674-86. PubMed ID: 8046239
[TBL] [Abstract][Full Text] [Related]
16. Human B cells and macrophages cooperate in T-cell-independent type 2 response.
Mättö M; Raunio AR; Postila V; Huttunen K; Hirvonen MR; Pelkonen J
Scand J Immunol; 2008 Mar; 67(3):209-17. PubMed ID: 18194360
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
[TBL] [Abstract][Full Text] [Related]
18. Toll-like receptor 9, transmembrane activator and calcium-modulating cyclophilin ligand interactor, and CD40 synergize in causing B-cell activation.
Ozcan E; Rauter I; Garibyan L; Dillon SR; Geha RS
J Allergy Clin Immunol; 2011 Sep; 128(3):601-9.e1-4. PubMed ID: 21741080
[TBL] [Abstract][Full Text] [Related]
19. T cells which do not express membrane tumor necrosis factor-alpha activate macrophage effector function by cell contact-dependent signaling of macrophage tumor necrosis factor-alpha production.
Suttles J; Miller RW; Tao X; Stout RD
Eur J Immunol; 1994 Aug; 24(8):1736-42. PubMed ID: 8056032
[TBL] [Abstract][Full Text] [Related]
20. Synergy of anti-CD40, CpG and MPL in activation of mouse macrophages.
Shi Y; Felder MA; Sondel PM; Rakhmilevich AL
Mol Immunol; 2015 Aug; 66(2):208-15. PubMed ID: 25829245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]